These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38024622)

  • 21. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse.
    Bachas C; Schuurhuis GJ; Reinhardt D; Creutzig U; Kwidama ZJ; Zwaan CM; van den Heuvel-Eibrink MM; De Bont ES; Elitzur S; Rizzari C; de Haas V; Zimmermann M; Cloos J; Kaspers GJ
    Br J Haematol; 2014 Sep; 166(6):902-10. PubMed ID: 24962064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted Therapies.
    Jalte M; Abbassi M; El Mouhi H; Daha Belghiti H; Ahakoud M; Bekkari H
    Cureus; 2023 Sep; 15(9):e45765. PubMed ID: 37872917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis.
    Hellesøy M; Engen C; Grob T; Löwenberg B; Valk PJM; Gjertsen BT
    Mol Oncol; 2021 Sep; 15(9):2285-2299. PubMed ID: 34101344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FLT3 and its role in the pathogenesis of acute myeloid leukaemia.
    Reilly JT
    Leuk Lymphoma; 2003 Jan; 44(1):1-7. PubMed ID: 12691136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.
    Wang W; Wang XQ; Xu XP; Lin GW
    J Int Med Res; 2010; 38(2):432-42. PubMed ID: 20515557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients.
    Salehzadeh S; Guerrini F; Pizzano U; Grassi S; Ciabatti E; Iovino L; Buda G; Caracciolo F; Benedetti E; Orciuolo E; Pelosini M; Consani G; Carulli G; Metelli MR; Martini F; Mazziotta F; Mazzantini E; Rossi P; Tavarozzi R; Ricci F; Petrini M; Galimberti S
    Cancer Cell Int; 2019; 19():83. PubMed ID: 30992690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications.
    Pallis M; Turzanski J; Grundy M; Seedhouse C; Russell N
    Br J Haematol; 2003 Mar; 120(6):1009-16. PubMed ID: 12648071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-specific analysis of FLT3 internal tandem duplications for the prognostication and monitoring of acute myeloid leukemia.
    Schiller J; Praulich I; Krings Rocha C; Kreuzer KA
    Eur J Haematol; 2012 Jul; 89(1):53-62. PubMed ID: 22458420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.
    Abu-Duhier FM; Goodeve AC; Wilson GA; Gari MA; Peake IR; Rees DC; Vandenberghe EA; Winship PR; Reilly JT
    Br J Haematol; 2000 Oct; 111(1):190-5. PubMed ID: 11091200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knock-in of the
    Annesley CE; Rabik C; Duffield AS; Rau RE; Magoon D; Li L; Huff V; Small D; Loeb DM; Brown P
    Oncotarget; 2018 Oct; 9(82):35313-35326. PubMed ID: 30450160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
    Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
    Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia.
    Esperanza-Cebollada E; Gómez-González S; Perez-Jaume S; Vega-García N; Vicente-Garcés C; Richarte-Franqués M; Rives S; Català A; Torrebadell M; Camós M
    Br J Haematol; 2023 Jul; 202(1):96-110. PubMed ID: 36951259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3-ITD mutations in acute myeloid leukaemia - molecular characteristics, distribution and numerical variation.
    Engen C; Hellesøy M; Grob T; Al Hinai A; Brendehaug A; Wergeland L; Bedringaas SL; Hovland R; Valk PJM; Gjertsen BT
    Mol Oncol; 2021 Sep; 15(9):2300-2317. PubMed ID: 33817952
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haematological & molecular profile of acute myelogenous leukaemia in India.
    Sazawal S; Kumar B; Hasan SK; Dutta P; Kumar R; Chaubey R; Mir R; Saxena R
    Indian J Med Res; 2009 Mar; 129(3):256-61. PubMed ID: 19491417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutated
    Niktoreh N; Walter C; Zimmermann M; von Neuhoff C; von Neuhoff N; Rasche M; Waack K; Creutzig U; Hanenberg H; Reinhardt D
    J Oncol; 2019; 2019():1609128. PubMed ID: 31467532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.